Cargando…

Integrated analysis of canine soft tissue sarcomas identifies recurrent mutations in TP53, KMT genes and PDGFB fusions

Soft tissue sarcomas (STS) are a heterogenous group of mesenchymal tumors representing over 50 distinct types with overlapping histological features and non-specific anatomical locations. Currently, localized sarcomas are treated with surgery + / − radiation in both humans and dogs with few molecul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Das, Sunetra, Idate, Rupa, Lana, Susan E., Regan, Daniel P., Duval, Dawn L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300023/ https://www.ncbi.nlm.nih.gov/pubmed/37369741 http://dx.doi.org/10.1038/s41598-023-37266-y

Ejemplares similares

Immune pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma
por: Das, Sunetra, et al.
Publicado: (2021)

The intratumor heterogeneity of TP53 gene mutations in canine histiocytic sarcoma
por: ASADA, Hajime, et al.
Publicado: (2019)

COL1A1-PDGFB fusion uterine sarcoma and its response to Imatinib therapy
por: Grindstaff, Samuel L., et al.
Publicado: (2020)

COL1A1::PDGFB fusion-associated uterine sarcoma and response to Imatinib: A case report
por: Chapagain, Udita, et al.
Publicado: (2023)

Case Report: A case of COL1A1–PDGFB fusion uterine sarcoma at cervix and insights into the clinical management of rare uterine sarcoma
por: Lu, Linghui, et al.
Publicado: (2023)

Extensive analysis of 59 sarcoma‐related fusion genes identified pazopanib as a potential inhibitor to COL1A1‐PDGFB fusion gene
por: Hirose, Takeshi, et al.
Publicado: (2023)

Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1–KMT2A–YAP1 and VIM–KMT2A fusions
por: Massoth, Lucas R., et al.
Publicado: (2020)

P315: TP53 ALTERATIONS AND MRD REFINE PROGNOSIS OF ADULT KMT2A-REARRANGED B-ALL
por: Kim, Rathana, et al.
Publicado: (2023)

The Brazilian TP53 mutation (R337H) and sarcomas
por: Volc, Sahlua Miguel, et al.
Publicado: (2020)

Non-chemotherapy adjuvant agents in TP53 mutant Ewing sarcoma
por: Kim, Jin-Ah, et al.
Publicado: (2023)

Rare myeloid sarcoma with KMT2A (MLL)-ELL fusion presenting as a vaginal wall mass
por: Bao, Haiyan, et al.
Publicado: (2019)

COL1A1-PDGFB fusion uterine fibrosarcoma: A case report with treatment implication
por: Grindstaff, Samuel L., et al.
Publicado: (2019)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Mutational status of K- ras and TP53 genes in primary sarcomas of the heart
por: Garcia, J M, et al.
Publicado: (2000)

Inherited and de novo germline TP53 mutations in adult-onset sarcoma
por: Thomas, David M, et al.
Publicado: (2012)

Inherited and de novo germline TP53 mutations in adult-onset sarcoma
por: Thomas, DM, et al.
Publicado: (2012)

TP53 Polymorphisms allow for genetic sub-grouping of the canine transmissible venereal tumor
por: Sánchez-Servín, Abel, et al.
Publicado: (2009)

Immunostaining for VEGF and Decorin Predicts Poor Survival and Recurrence in Canine Soft Tissue Sarcoma
por: Bray, Jonathan P., et al.
Publicado: (2023)

KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study
por: Ferrero, Simone, et al.
Publicado: (2020)

Familial Brain Calcifications With Leukoencephalopathy: A Novel PDGFB Variant
por: Shen, Jack, et al.
Publicado: (2022)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

Canine tumor mutational burden is correlated with TP53 mutation across tumor types and breeds
por: Alsaihati, Burair A., et al.
Publicado: (2021)

Establishment of TP53-knockout canine cells using optimized CRIPSR/Cas9 vector system for canine cancer research
por: Eun, Kiyoung, et al.
Publicado: (2019)

High Frequency of Germline TP53 Mutations in a Prospective Adult-Onset Sarcoma Cohort
por: Mitchell, Gillian, et al.
Publicado: (2013)

Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements
por: Trauernicht, Max, et al.
Publicado: (2023)

Lrig2-Deficient Mice Are Protected against PDGFB-Induced Glioma
por: Rondahl, Veronica, et al.
Publicado: (2013)

White matter involvement in a family with a novel PDGFB mutation
por: Biancheri, Roberta, et al.
Publicado: (2016)

A systems genetics approach to revealing the Pdgfb molecular network of the retina
por: Li, Shasha, et al.
Publicado: (2020)

Living with primary brain calcification with PDGFB variants: A qualitative study
por: Takeuchi, Tomiko, et al.
Publicado: (2022)

The TP53 fertility network
por: Paskulin, Diego d’Avila, et al.
Publicado: (2012)

TP53: an oncogene in disguise
por: Soussi, T, et al.
Publicado: (2015)

TP53 in Myelodysplastic Syndromes
por: Jiang, Yan, et al.
Publicado: (2021)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

Alternative splicing of Apoptosis Stimulating Protein of TP53-2 (ASPP2) results in an oncogenic isoform promoting migration and therapy resistance in soft tissue sarcoma (STS)
por: Tsintari, Vasileia, et al.
Publicado: (2022)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015)

Preclinical Evaluation of Oncolytic Vaccinia Virus for Therapy of Canine Soft Tissue Sarcoma
por: Gentschev, Ivaylo, et al.
Publicado: (2012)

Somatic intronic TP53 c.375+5G mutations are a recurrent but under‐recognized mode of TP53 inactivation
por: Chui, M Herman, et al.
Publicado: (2021)

Expression of TP53 Isoforms p53β or p53γ Enhances Chemosensitivity in TP53(null) Cell Lines
por: Silden, Elisabeth, et al.
Publicado: (2013)

Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations
por: Lorenz, Susanne, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vobktbvuaq3q759cbfpri3n7r7